Safety & Transparency
Dietary supplements are not risk-free. Safe use starts with the current label, a complete list of medicines and supplements, and product-specific advice from a qualified healthcare professional.
This page separates emergency care, poisoning help, adverse-event reporting, quality complaints, and the evidence limits of testing records.
Reporting is not emergency care
Call 911 now for collapse, a seizure, inability to wake, trouble breathing, severe swelling of the face, tongue, or throat, severe chest pain, signs of stroke, or uncontrolled severe bleeding.
For a suspected poisoning or overdose in the United States without immediate life-threatening danger, call Poison Control at 1-800-222-1222 or use webPOISONCONTROL. Do not wait for REVESYN or FDA to reply.
Ask a qualified healthcare professional before use if any of these apply
-
Medicines or treatment
Bring a complete list of prescriptions, over-the-counter medicines, supplements, antacids, laxatives, and fortified products.
-
A health condition
Kidney, liver, bleeding, blood-pressure, glucose, heart-rhythm, allergy, psychiatric, gastrointestinal, and other conditions can change risk.
-
Pregnancy, breastfeeding, or trying to conceive
Evidence is often limited and product-specific. A label warning does not replace individualized advice.
-
Child or adolescent
Adult supplement directions should not be assumed appropriate for a child or adolescent.
-
Procedure or surgery
Tell the surgical team about every supplement; some can affect bleeding, blood pressure, glucose, sedation, or testing.
-
Previous reaction
A prior allergic or unusual reaction increases the need for professional review and clear ingredient identification.
Interactions are ingredient-, dose-, and person-specific
Do not use a generic interaction list as clearance for an individual. A pharmacist or prescriber should review exact labels, doses, timing, conditions, and treatment goals.
Can reduce absorption of oral bisphosphonates and some tetracycline or quinolone antibiotics. Diuretics and long-term proton-pump inhibitor use can affect magnesium status.
Interaction concerns can include warfarin, insulin, and some cancer-treatment contexts. Evidence and clinical relevance are condition-specific.
Bleeding, surgery, medicines, and long-term safety require caution. Short trials without serious events do not prove absence of interaction risk.
Human safety exposure is limited; GI symptoms and hypersensitivity have been reported. Product material and individual allergy history matter.
Available trials are generally small and short. Long-term, uncommon, disease-specific, and medication-interaction risks remain unresolved.
Using more than one product
-
Make one complete list
Record every ingredient, amount per serving, number of servings, timing, and all medicines and fortified products.
-
Check for duplicates
Add total daily amounts by elemental nutrient or active ingredient—not by front-label blend weight.
-
Do not create a higher serving
More is not automatically more effective. Do not combine products to recreate a study dose without professional guidance.
-
Add products cautiously
Starting several products together can make it difficult to identify the cause of a reaction.
-
Treat bundles separately
A pathway rationale is not a combined-safety study, and a bundle does not establish synergy or interaction absence.
No reported event is not proof of no risk
Small, short trials can miss uncommon, delayed, interaction-related, pregnancy-related, or long-term effects. Generally well tolerated describes observations under studied conditions; it does not mean safe for everyone.
Nausea, abdominal discomfort, loose stools, diarrhea, or vomiting can occur with some supplements. Severe or persistent symptoms need medical assessment.
Itching, hives, rash, wheezing, or swelling can signal a reaction. Stop use and seek urgent help; call 911 for trouble breathing, collapse, or severe face, tongue, or throat swelling.
Severe headache, marked confusion, unusual drowsiness, dizziness, fainting, palpitations, mood changes, or low-blood-sugar symptoms should not be dismissed.
An adverse event is an unwanted occurrence during or after use. A report does not by itself prove that the product caused it, but uncertainty is not a reason to ignore or withhold a report.
When to stop, seek help, or call 911
-
Life-threatening emergency
Call 911 now. Do not complete a web form or wait for a company response.
-
Suspected poisoning or overdose
Call Poison Control at 1-800-222-1222 in the U.S.; use 911 for collapse, seizure, trouble breathing, or inability to wake.
-
Suspected serious reaction
Stop the suspected supplement, seek medical care promptly, keep the container or label photos, and report the event.
-
Non-emergency concern
Pause the suspected product and contact a qualified healthcare professional if symptoms persist, recur, or affect daily function.
How to report a suspected adverse event
-
1. Get care first
Use 911, Poison Control, urgent care, or your healthcare professional according to the situation.
-
2. Use the current label contact
Report to the domestic phone number or address printed on the exact product label. A general contact form is not an emergency or medical-reporting channel.
-
3. Preserve details
Keep product name, lot code, expiration date, order details, use dates, symptoms, outcome, other medicines, label photos, and care received.
-
4. Report to FDA
Consumers and healthcare professionals can use FDA’s dietary-supplement reporting route and Safety Reporting Portal.
FDA reporting is available even when causation is uncertain
You do not need to be certain that a dietary supplement caused an event to report it. FDA’s consumer route explains online reporting and current form options.
Submission does not prove causation, and a lack of reports does not prove safety. Form FDA 3500A is an industry route, not the consumer voluntary form.
FDA: How to report a dietary-supplement problem · Safety Reporting Portal
Product quality complaints
-
Do not use a compromised product
Examples include a broken seal, damaged container, unreadable or incorrect label, foreign material, leakage, or an unexpected odor or appearance.
-
Keep identifying information
Preserve the product, packaging, lot code, expiration date, order number, shipping box when relevant, and clear photos.
-
Use verified support details
Use the current label or order contact and state whether anyone used the product or experienced a health event.
-
Complaint ≠ proven defect
A complaint begins a documented review; it does not by itself establish a defect or medical causation.
Testing records are important—but they do not prove every outcome
FDA does not approve dietary supplements for safety and effectiveness before marketing. Manufacturers and distributors are responsible for lawful ingredients, manufacturing, labeling, safety, and truthful, substantiated claims.
Testing, COAs, cGMP controls, certifications, and supplier records do not prove clinical efficacy, suitability for every person, zero contamination, zero risk, or a current-lot guarantee unless the exact record and lot relationship are established.
Review Testing & Verification · Review the evidence methodology
Review the exact product label before use
-
NMN 500 mg
Review the current label, serving, other ingredients, directions, and warnings.
-
CoQ10 Ubiquinone 200 mg
Review the current label and medication-interaction context.
-
Resveratrol 50% 600 mg
Review the exact material, serving, other ingredients, and warnings.
-
Lion’s Mane Mushroom
Review material identity, serving, other ingredients, and allergy context.
-
Magnesium Glycinate 275 mg
Review elemental magnesium, serving, other sources, kidney risk, and medication timing.
Read the ingredient evidence separately
-
NMN human evidence
Short-term target engagement and outcome limits.
-
CoQ10 human evidence
Formulation, exposure, outcomes, and safety boundaries.
-
Resveratrol human evidence
Pharmacokinetics, heterogeneous trials, and interaction uncertainty.
-
Lion’s Mane human evidence
Preparation-specific studies, null findings, and preclinical boundaries.
-
Magnesium glycinate evidence
Elemental dose, form, sleep evidence, and safety context.
Where project compliance documents come from
REVESYN uses the Supliful product compliance index as the canonical supplier-document source for this project. The records support exact label, ingredient, and quality review only within their documented scope.
A supplier record does not establish clinical efficacy, an outcome for the finished REVESYN product, absence of every contaminant, or a current-lot guarantee without a verified lot relationship.
Review the exact product before use
Recheck the current label even if you have used an earlier lot or version. Include active and other ingredients, elemental or active amount, serving size, directions, warnings, allergen information, and the domestic adverse-event contact.
This page provides general U.S. consumer safety information and is not medical advice. For personalized questions about medicines, conditions, pregnancy, breastfeeding, surgery, symptoms, or dosing, contact a qualified healthcare professional.
Selected references
Each source is linked directly and paired with the interpretation boundary used on this page. Evidence cutoff: August 23, 2026; official links rechecked September 16, 2026.
U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements. Official page rechecked September 16, 2026.
Supports the premarket framework and firm responsibilities; FDA does not approve supplements for safety and effectiveness before marketing.
U.S. Food and Drug Administration. FDA 101: Dietary Supplements. Official page rechecked September 16, 2026.
Supports label use, combination risks, and the natural-does-not-mean-safe boundary.
U.S. Food and Drug Administration. How to Report a Problem with Dietary Supplements. Official page rechecked September 16, 2026.
Reporting is not emergency care and a report does not prove causation.
U.S. Food and Drug Administration. Questions and Answers Regarding Adverse Event Reporting and Recordkeeping for Dietary Supplements. Final guidance, September 2013.
Industry guidance; current business responsibilities and agreements require qualified legal review.
National Center for Complementary and Integrative Health. Coenzyme Q10. Official page rechecked September 16, 2026.
Broad safety and interaction context, not product-specific advice.
NIH Office of Dietary Supplements. Magnesium: Fact Sheet for Health Professionals. Official page rechecked September 16, 2026.
Supports GI effects, the supplemental UL, renal risk, and selected medication interactions.
National Institute of Diabetes and Digestive and Kidney Diseases. Lion’s Mane. LiverTox. Updated January 5, 2024.
Limited human exposure and an absence of identified liver injury are not comprehensive or product-specific safety evidence.
Yadegar S, et al. Effects and safety of resveratrol supplementation in older adults. Phytother Res. 2024;38:2448–2461. PMID 38433010.
Ten heterogeneous trials do not establish long-term safety, an optimal dose, or interaction absence.
Yang W, et al. Safety and metabolism-related outcomes of oral NMN supplementation in adults. Nutrients. 2026;18:2251. PMID 42514320.
Short trials and small samples leave long-term and uncommon effects unresolved.
U.S. Food and Drug Administration. When and Where to Report Emergencies. Official page rechecked September 16, 2026.
Call 911 for a current life-threatening medical emergency; reporting channels are not emergency care.
Poison Control — National Capital Poison Center. Get Help for a Poisoning. Route and phone rechecked September 16, 2026.
In the U.S., call 1-800-222-1222 for a suspected poisoning or overdose; call 911 for collapse, seizure, trouble breathing, or inability to wake.
U.S. Food and Drug Administration. Labeling of Dietary Supplements under the Dietary Supplement and Nonprescription Drug Consumer Protection Act. Guidance, September 2009.
Supports domestic address or phone labeling context; not evidence of product approval.
Electronic Code of Federal Regulations. 21 CFR Part 111 — Current Good Manufacturing Practice for Dietary Supplements.
cGMP and complaint records do not prove clinical efficacy, zero risk, or a current-lot guarantee.
